Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma

Annals of Nuclear Medicine

Volumn 26, Issue 3, 2012, Pages 262-271

  Matsushima, Nobuyoshi ^a   Maeda, Masayuki ^a   Umino, Maki ^a   Suzawa, Naohisa ^a   Yamada, Tomomi ^a   Takeda, Kan ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

ADC; FDG PET CT; Glioma; Lymphoma; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; LYMPHOMA; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CHILD; DIAGNOSIS, DIFFERENTIAL; DIFFUSION; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862694164     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0570-y     Document Type: Article

References (37)

1. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991;32:616-22.
2. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET. Radiology. 1995;195:47-52.
3. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-37.
4. Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18] fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. J Otorhinolaryngol Relat Spec. 2001;63: 307-13.
5. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-44.
6. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-9.
7. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33: 683-91.
8. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol. 2009;11:473-9.
9. Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med. 2009;23:89-95.
10. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771-5.
11. Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. Am J Roentgenol. 2007;188: 1223-31.
12. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39:1002-7.
13. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239:632-49.
14. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401-7.
15. Cha S. Update on brain tumor imaging: from anatomy to physiology. Am J Neuroradiol. 2006;27:475-87.
16. Yang D, Korogi Y, Sugahara T, Kitajima M, Shigematsu Y, Liang L, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology. 2002;44:656-66.
17. Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, et al. The role of diffusion-weighted imaging in patients with brain tumors. Am J Neuroradiol. 2001;22:1081-8.
18. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology. 2005;235:985-91.
19. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53-60.
20. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839-46.
21. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. Am J Roentgenol. 2008;190:365-9.
22. Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol. 2008;35:171-6.
23. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. Am J Neuroradiol. 2008;29:1176-82.
24. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. Am J Neuroradiol. 2008;29:471-5.
25. Makino K, Hirai T, Nakamura H, Murakami R, Kitajima M, Shigematsu Y, et al. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med. 2011;25:432-8.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
27. Palumbo B, Angotti F, Marano GD. Relationship between PETFDG and MRI apparent diffusion coefficients in brain tumors. Q J Nucl Med Imaging. 2009;53:17-22.
28. Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging. 2010;37:2011-20.
29. Gu J, Khong PL, Wang S, Chan Q, Law W, Zhang J. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol. 2011;13:1020-8.
30. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36:200-8.
31. Bénard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med. 2003;33:148-62.
32. Murakami R, Hirai T, Sugahara T, Fukuoka H, Toya R, Nishimura S, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus twoparameter pilot method. Radiology. 2009;251:838-45.
33. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med. 1999;26:1501-9.
34. Meyer PT, Schreckenberger M, Spetzger U, Meyer GF, Sabri O, Setani KS, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165-74.
35. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-87.
36. Stadnik TW, Demaerel P, Luypaert RR, Chaskis C, Van Rompaey KL, Michotte A, et al. Imaging tutorial: differential diagnosis of bright lesions on diffusion-weighted MR images. Radiographics. 2003;23:e7.
37. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252: 182-9.